Interleukin-6 as a biomarker of treatment success for temporomandibular joint disorders

Authors

  • Francisco Cid Trejo Universidad de Chile
  • Benjamín Sanhueza Bastías Universidad de Chile
  • Daniela Ibazeta Serei Universidad de Chile
  • Sonja Buvinic Radic Universidad de Chile

DOI:

https://doi.org/10.22370/asd.2020.1.0.2625

Keywords:

Interleukin-6, Temporomandibular Disorders, Treatment

Abstract

Objective: To evaluate IL-6 level changes in synovial fluid (SF) in the temporomandibular joint (TMJ) post-treatment of temporomandibular disorders (TMD).  

Material and Methods: In a first search, MeSH terms were used in Pubmed. A second one was conducted in Pubmed and the Cochrane Library, with MeSH terms and keywords in an advanced search. Inclusion criteria were all systematic reviews since 2015 on treatments for TMD, and clinical studies since 2015 where IL-6 levels were measured in SF post-treatment of TMD. Exclusion criteria were all studies where IL-6 levels were measured in plasma or joint tissue.

Results: In the first search41 results were obtained per title and abstract, of which 15 systematic reviews remained meeting the inclusion criteria. In a second search, 35 results were obtained, of which 28 were excluded by title and abstract as they were not pertinent. After full reading, three randomized clinical studies remained that met the inclusion criteria. 

Conclusion: It is necessary to continue considering new therapeutic strategies to decrease levels of pro-inflammatory cytokines, where IL-6 might become a possible biomarker in TMD.

Published

2021-01-10

How to Cite

Cid Trejo, F., Sanhueza Bastías, B., Ibazeta Serei, D., & Buvinic Radic, S. (2021). Interleukin-6 as a biomarker of treatment success for temporomandibular joint disorders. Applied Sciences in Dentistry, 1. https://doi.org/10.22370/asd.2020.1.0.2625

Issue

Section

Reviews

Most read articles by the same author(s)